1,216
Participants
Start Date
September 11, 2017
Primary Completion Date
August 9, 2019
Study Completion Date
November 20, 2019
Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
Different facilities, Multiple Locations
Different facilities, Multiple Locations
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY